首页> 外文OA文献 >Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis

【2h】

Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis

机译：Lenvatinib延长了患者中期肝细胞癌难治性的无进展生存时间令人难以理解的ryarterial Chemoembolization：使用数据挖掘分析的多中心队列研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Shigeo Shimose; Takumi Kawaguchi; Masatoshi Tanaka; Hideki Iwamoto; Ken Miyazaki; Etsuko Moriyama; Hiroyuki Suzuki; Takashi Niizeki; Tomotake Shirono; Masahito Nakano; Hideya Suga; Taizo Yamaguchi; Yoshinori Yokokura; Kazunori Noguchi; Hironori Koga; Takuji Torimura;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study [J] . Chao-Bin He, Xiang-Ming Lao, Xiao-Jun Lin Cancer Communications . 2017,第1期

机译：经动脉化学栓塞联合5型H101重组人腺病毒可延长中晚期肝细胞癌患者的总生存期：诺模图预后研究
2. Transarterial chemoembolization combined with recombinant human adenovirus type?5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study [J] . Chao-Bin He, Xiang-Ming Lao, Xiao-Jun Lin Chinese journal of cancer . 2017,第1期

机译：经动脉化学栓塞联合重组人5型H101腺病毒可延长中晚期肝细胞癌患者的总生存期：诺模图预后研究
3. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study [J] . Wen Ping, Chen Sheng-Duo, Wang Jia-Rui, Oncology Research . 2019,第5期

机译：药物洗脱珠霉变化疗与中国肝细胞癌患者常规龙霉栓塞之间治疗响应和存活谱的比较：临时队列研究
4. Evaluation of hepatocellular carcinoma transarterial chemoembolization using 3D contrast enhanced ultrasound time-intensity curve analysis [C] . Kibo Nam, Maria Stanczak, Flemming Forsberg, IEEE International Ultrasonics Symposium . 2017

机译：使用3D对比增强超声时间强度曲线分析评估肝细胞癌经动脉化疗栓塞
5. Novel methodologies for the analysis of complex failure time data and alternative progression -free survival estimators. [D] . Zhang, Jing (Jenny). 2008

机译：用于分析复杂故障时间数据和替代无进展生存估计器的新颖方法。
6. Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study [O] . Jun Sik Yoon, Dong Hyun Sinn, Jeong-Hoon Lee, 2019

机译：基于肿瘤标记物的中级肝细胞癌经动脉化疗栓塞-难治性定义：多队列研究
7. Abstract No. 37 LEAP-012 trial in progress: pembrolizumab, lenvatinib, and transarterial chemoembolization combination therapy for intermediate-stage hepatocellular carcinoma not amenable to curative treatment [O] . D. Madoff, J. Llovet, A. El-Khoueiry, 2021

机译：摘要37号LEAP-012试验正在进行中：彭布洛司，Lenvatinib和rantarial Chemoembolization组合治疗中间阶段肝细胞癌不适合治疗治疗

Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis

著录项

引文网络

相似文献

相关主题

期刊订阅